Literature DB >> 6611596

Induction of hepatic protein synthesis by a peptide in blood plasma of patients with sepsis and trauma.

M Loda, G H Clowes, C A Dinarello, B C George, B Lane, W Richardson.   

Abstract

Accelerated release of amino acids from muscle and their uptake for protein synthesis by liver and other visceral tissues are characteristic of trauma or sepsis. Experimentally, this response is induced by interleukin-1 (IL-1) generated by activated macrophages in vitro. However, IL-1 has not been demonstrated in human blood. A small 4000-dalton peptide recently isolated from plasma of patients with sepsis and trauma induces muscle proteolysis and is called "proteolysis-inducing factor" (PIF). To test whether this agent has the ability also to induce hepatic protein synthesis, a series of animal experiments and clinical observations were undertaken. The structural and secretory (acute-phase reactants) in vitro protein synthesis in livers of normal rats injected intraperitoneally with IL-1 or PIF was significantly greater than that of normal rats or those injected with Ringer's lactate (p less than 0.01). In patients with sepsis and trauma the central plasma clearance rate of amino acids, a measure of visceral (principally hepatic) amino acid uptake, was elevated and correlated with the rates of protein synthesis in incubated liver slices obtained by biopsy at operation from the same patients (p less than 0.05). Both in vivo measured central plasma clearance rate of amino acids and in vitro measured hepatic protein synthesis correlated with plasma levels of PIF in the same patients (p less than 0.01 and p less than 0.05, respectively). We conclude that since PIF, and not IL-1, is present in human plasma and both are produced by activated macrophages, PIF seems to be the stable circulating cleavage product of IL-1, which induces not only muscle proteolysis but also hepatic protein synthesis, principally in the form of acute-phase reactants during infection and other states in which inflammation is present.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611596

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Hepatic dysfunction during bacterial sepsis.

Authors:  A E Gimson
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

2.  Shock. A century of progress.

Authors:  L D MacLean
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

3.  Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase.

Authors:  M D Nawabi; K P Block; M C Chakrabarti; M G Buse
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  Effect of indomethacin on postoperative protein metabolism after gastrectomy under total parenteral nutrition.

Authors:  T Tsujinaka; Y Kido; Y Hayashida; A Ogawa; H Ishida; T Homma; S Iijima; M Sakaue; T Mori
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Hepatic serine and alanine metabolism during endotoxin-induced fever in sheep.

Authors:  B G Southorn; J R Thompson
Journal:  Can J Vet Res       Date:  1987-07       Impact factor: 1.310

6.  Survival from hepatic transplantation. Relationship of protein synthesis to histological abnormalities in patient selection and postoperative management.

Authors:  R L Jenkins; G H Clowes; S Bosari; R H Pearl; U Khettry; C Trey
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

7.  Survival from sepsis. The significance of altered protein metabolism regulated by proteolysis inducing factor, the circulating cleavage product of interleukin-1.

Authors:  G H Clowes; E Hirsch; B C George; L M Bigatello; J E Mazuski; C A Villee
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

8.  Inhibited muscle amino acid uptake in sepsis.

Authors:  P O Hasselgren; J H James; J E Fischer
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.